MilliporeSigma Collaborates with Evotec for Faster Target Identification Solution
- Accelerates screening of customized CRISPR and shRNA libraries
- Eliminates need for resource-intensive in-house assay development and screening
Billerica, Massachusetts, November 30, 2016 — MilliporeSigma today announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for MilliporeSigma’s collection of genetic reagents such as CRISPR and shRNA libraries. Combining access to these libraries with Evotec’s screening expertise offers an accelerated pathway to explore and identify new drug targets.
“Drug discovery starts with the identification of new targets, a process that can be time- and labor-intensive,” said Theresa Creasey, Head of Applied Solutions Strategic Marketing & Innovation, MilliporeSigma. “Our collaboration with Evotec accelerates the discovery workflow, enabling customers to more rapidly and efficiently explore disease pathways and find new targets.”
The collaboration allows customers to select a customized set of CRISPR and shRNA libraries, and then leverage Evotec’s extensive capabilities in phenotypic screening within primary and induced pluripotent stem cells and in vivo disease models. The target identification workflow is further accelerated through the use of custom-engineered cell lines developed by MilliporeSigma’s Cell Design Studio. These cell lines are used by Evotec to customize screening assays and deliver answers more efficiently.
“This agreement with MilliporeSigma further strengthens our offering in the area of target identification and validation,” said Mario Polywka, PhD, Chief Operating Officer of Evotec. “Deploying MilliporeSigma’s assay-ready reagents on our cellular screening platforms and in vivo models creates powerful drug discovery capabilities and more value to our customers through such a comprehensive solution.”
MilliporeSigma partners with the Wellcome Trust Sanger Institute for its arrayed CRISPR library covering the entire human genome. The company is also the manufacturer and distributor of the world’s largest RNAi clone library, created in collaboration with The RNAi Consortium.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.